Aptose Biosciences Inc.
Business
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision small-molecule oncology therapies for hematologic malignancies. It advances oral targeted kinase inhibitors, principally tuspetinib and luxeptinib, designed for single-agent activity and combination regimens to overcome resistance and minimize overlapping toxicities. Its business is organized around clinical development programs, licensing arrangements and preclinical research supporting the tuspetinib and luxeptinib programs. The company conducts international clinical trials and pursues regulatory and commercialization pathways through collaborations and licensing in North America, Europe and Asia.
Summary from filing dated 2025-03-28
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 11 | 15 | 33 | 25 | 46 | |
| General and administrative | 13 | 11 | 16 | 15 | 19 | |
| Total operating expenses | 25 | 26 | 52 | 43 | 65 | |
| Interest income | 105,000 | 357,000 | 1 | 788,000 | 94,000 | |
| Interest expense, related party | −843,000 | −207,000 | 0 | — | — | |
| Change in fair value of warrants | 0 | 686,000 | 0 | — | — | |
| Foreign exchange loss | −7,000 | −9,000 | −2,000 | −9,000 | −1,000 | |
| Total other (expenses) income | −745,000 | 827,000 | 1 | 779,000 | 93,000 | |
| Net loss and comprehensive loss | −26 | −25 | −51 | −42 | −65 | |
| Net loss per common share, basic | −10.41 | −36.38 | −227.43 | −6.8 | −0.73 | |
| Net loss per common share, diluted | −10.41 | −36.38 | −227.43 | −6.8 | −0.73 | |
| Weighted-average number of common shares outstanding, basic | 2 | 698,980 | 225,154 | 6 | 89,086 | |
| Weighted-average number of common shares outstanding, diluted | 2 | 698,980 | 225,154 | 6 | 89,086 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 935,000 | 6 | 9 | 37 | 39 | |
| Restricted cash and restricted cash equivalents | 3 | 555,000 | — | — | — | |
| Prepaid expenses | 2 | 2 | 2 | 2 | 2 | |
| Other current assets | 141,000 | 570,000 | 600,000 | 257,000 | 133,000 | |
| Total current assets | 6 | 10 | 12 | 50 | 82 | |
| Property and equipment, net | 4,000 | 26,000 | 152,000 | 211,000 | 323,000 | |
| Right-of-use assets, operating leases | 175,000 | 571,000 | 943,000 | 1 | 465,000 | |
| Other long-term assets | 3 | 0 | — | — | — | |
| Total non-current assets | 4 | 597,000 | 1 | 2 | 788,000 | |
| Total assets | 10 | 10 | 13 | 51 | 83 | |
| Accounts payable | 3 | 1 | 3 | 3 | 2 | |
| Accrued liabilities | 6 | 3 | 9 | 5 | 6 | |
| Current portion of lease liability, operating leases | 193,000 | 428,000 | 394,000 | 301,000 | 459,000 | |
| Total current liabilities | 9 | 4 | 15 | 12 | 8 | |
| Lease liability, operating leases | 0 | 193,000 | 621,000 | 1 | 115,000 | |
| Loan payable to related party | 27 | 10 | — | — | — | |
| Interest on related party loan payable | 855,000 | 18,000 | — | — | — | |
| Total non-current liabilities | 28 | 10 | 621,000 | — | — | |
| Total liabilities | 37 | 15 | 16 | 13 | 8 | |
| Common shares, no par value, unlimited authorized shares, 2,552,429 and 2,006,028 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 460 | 457 | 445 | 438 | 437 | |
| Additional paid-in capital | 84 | 83 | 72 | 69 | 64 | |
| Accumulated other comprehensive loss | −4 | −4 | −4 | −4 | −4 | |
| Accumulated deficit | −566 | −541 | −516 | −464 | −423 | |
| Total shareholders' deficit | −27 | −5 | −3 | 38 | 74 | |
| Total liabilities and shareholders' deficit | 10 | 10 | 13 | 51 | 83 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 477,000 | 1 | 4 | 5 | 13 | |
| Depreciation of property and equipment | 22,000 | 32,000 | 88,000 | — | — | |
| Loss on disposal of property and equipment | 0 | 76,000 | 0 | 16,000 | 0 | |
| Noncash operating lease expense | 396,000 | 372,000 | — | — | — | |
| Interest on lease liabilities | 34,000 | 64,000 | 93,000 | 35,000 | 43,000 | |
| Interest on loan payable to related party | 843,000 | 18,000 | 0 | — | — | |
| Prepaid expenses | 44,000 | −211,000 | 261,000 | 173,000 | 78,000 | |
| Other assets | −3 | 30,000 | −343,000 | −124,000 | −4,000 | |
| Change in operating lease liability | −462,000 | −458,000 | — | — | — | |
| Accounts payable | 2 | −2 | 0 | — | — | |
| Accounts payable, related party | 0 | −3 | −430,000 | 3 | — | |
| Accrued liabilities | 3 | −6 | 4 | −4 | 2 | |
| Cash used in operating activities | −22 | −36 | −45 | −32 | −43 | |
| Proceeds from disposal of property and equipment | 0 | 23,000 | 0 | — | — | |
| Purchase of property and equipment | 0 | −5,000 | −29,000 | −24,000 | −212,000 | |
| Cash provided by investing activities | 0 | 18,000 | 10 | 30 | −35 | |
| Proceeds from loan payable with related parties | 19 | 10 | 0 | — | — | |
| Repayment of loan with related party | −100,000 | 0 | — | — | — | |
| Cash provided by financing activities | 19 | 33 | 7 | 116,000 | 226,000 | |
| Decrease in cash, cash equivalents, restricted cash and restricted cash equivalent | −3 | −3 | −28 | −2 | −78 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Aptose Biosciences Inc.'s CIK number?
Aptose Biosciences Inc.'s SEC CIK number is 0000882361 (882361). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Aptose Biosciences Inc.'s SEC filings?
All of Aptose Biosciences Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.